Enterosgel - a medical product with a potentially wide range of applications

Abstract:

Medical product Class IIa Enterosgel hydrogel is based on polymethyilsiloxane that is obtained by polycondensation of methyl silicate acid, with a loss of water and formation of siloxane bonds (Si-O-Si). Through the drying of organic silica gel the solid mesoporous adsorbent (xerogel) is produced, with a specific surface area of 300 m2 g-1. The portion of xerogel in the medical product Enterosgel is about 7%. The process of adsorption by Enterosgel takes place by two mechanisms - molecular adsorption and co-sedimentation in the gel. Compared with activated carbon, which is usually administered as an oral adsorbent (enterosorbent), Enterosgel has a lower capacity to the compounds with a molecular mass of less than 1500 Da, but is a far more potent adsorbent for binding to high molecular weight compounds, such as proteins and bacterial endotoxins, than the activated carbon is. Numerous experimental and clinical studies investigated the oral administration of Enterosgel in the treatment of gastrointestinal diseases, renal failure, diabetes, hyperlipidemia, allergic conditions such as asthma, eczema and allergic dermatitis, burns, polytrauma, sepsis and multiple organ failure in the preoperative period with the risk of losing large amounts of blood, and in oncology in order to reduce side effects of chemotherapy and various intoxications (heavy metals, organophosphate pesticides, occupational poisonings - benzene, cyclohexane). 

Key words:
bacterial infections; chemotherapy; gastrointestinal tract; oral adsorption; polymethyilsiloxane; viral infections